Роль цитокиновой сети в регуляции воспаления при различных вариантах ювенильного артрита
https://doi.org/10.14412/1995-4484-2009-1316
Аннотация
Хронические артриты у детей являются важной проблемой современной педиатрии в силу того, что эти тяжелые заболевания существенно нарушают качество жизни ребенка и его родителей, требуют немалых экономических затрат на лечение и нередко приводят к инвалидности ребёнка. Этиология этих заболеваний в настоящее время окончательно не расшифрована, существует лишь ряд более или менее обоснованных гипотез на этот счет. Лечение ювенильных артритов (ЮА), несмотря на значительные успехи, достигнутые в последние десятилетия, также далеко от совершенства: подбор медикаментозных средств зачастую производится эмпирически, не всегда врачу удается контролировать патологический процесс и предотвратить серьезные функциональные нарушения. Любой значительный прорыв в терапии хронических артритов у детей может быть достигнут только при условии прогресса в понимании патогенеза этих заболеваний и механизмов действия лекарственных препаратов, направленных на конкретные звенья патологического процесса. Появление в последние годы новых классов лекарственных препаратов, так называемых биологических противовоспалительных агентов, особенно остро ставит вопрос об участии определенных механизмов в формировании различных форм ЮА, без чего невозможно грамотное назначение данных лекарств у конкретного больного.
Список литературы
1. <div><p>Насонов Е.Л. Противовоспалительная терапия ревматических болезней М. «М-Сити», 1996,</p><p>Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии Ярославль, «Верхняя Волга», 1999</p><p>Ярилин А.А. Основы иммунологии. М. «Медицина», 1999</p><p>Dinarello C.A., Mondawer L.L. Proinflammatory and Anti-inflammatory Cytokines in Rheumatoid Arthritis. A primer for cliniciens. Second Ed. Amgen Inc. 2000.</p><p>Кетлинский С.А., Симбирцев А.С. Цитокины. С.П. «Фолиант», 2008</p><p>Prieur A.M., Roux Lombard P., Dayer J.M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rheum. Engl. Ed., 1996, 63,163-70.</p><p>Prieur A.M., Kaufmann M.T., Griscelli C., Dayer J.M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthri- tis. Lancet, 1987, 1240-42.</p><p>Rooney M., David J., Symons J., et al. Inflammatory cytokine response in juvenile chronic arthritis. Br. J. Rheumatol. 1995, 34,454-60.</p><p>Shahin A.A, Shaker O.G., Kamal N, et al. Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol. Int. 2002,22,84-8</p><p>De Benedetti F, Massa M, Pignatti P. et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 1994, 93,2114-9.</p><p>De Benedetti F, Pignatti P, Gerloni V. et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol., 1997, 24,1403-9. 87</p><p>Muller K, Herner EB, Stagg A, et al. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br. J. Rheumatol., 1998,37,562-9.</p><p>Woo P. The Cytokine network in juvenile chronic arhritis. Ann. Med., 1997,29,145-7.</p><p>De Benedetti F, Pignatti P, Massa M. et al. Circulating levels of interleukin 1 beta and interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin. Exp. Rheumatol. 1995,13,779-84.</p><p>Yilmaz M, Kendirli S.G, Altintas D. et al. Cytokine levels in serum of patients with juvenile rheumatoid arthritis.Clin. Rheumatol. 2001,20,30-5.</p><p>Mangge H., Kenzian H., Gallistl S. et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with convential inflammatiom parametrs and clinical subtypes. Arthritis. Rheum., 1995, 3,211-20.</p><p>Ozen S., N.Saatci, Bakkaroglu A. et al. Interleukin-1,-6,-8 levels in juvenile chronic Arthrititis. Clin.Rheumatol., 1997, 16, 173-8.</p><p>De Benedetti F, Pignatti P, Bernassconi S. et al.Interleukin 8 and monocyte chemoattractant protein-1 in patient with juvenile rheumatoid arthritis: relation to onset types, disease activity and synovial fluid leukocytes. J.Rheumatol. 1999, 26,425-31.</p><p>Pascual V., Allantaz F., Arce E., Punaro M. Role of interleukin-1 (IL-1) in the patogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med., 2005, 201, 1479-86.</p><p>De Benedetti F., Ravelli A., Martini A. Cytokines in juvenile rheumatiod artritis. Curr. Opin. Rheumatol., 1997. 9.428-33.</p><p>De Benedetti F. Inflammatory cytokines in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediat. Rheumatol. Online J., 2005, 3, 122-36.</p><p>De Benedetti F., Meazza C., Olvery M., et al. Effect of IL-6 on IGF binding protein-3: A study in IL-6 transgenic mise and in patients with systemic juvenile arthritis. Endocrinol., 2001, 142, 4818-26.</p><p>De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease? J.Rheumatol., 1998, 25, 203-7</p><p>De Benedetti F., Martini A. Targeting in the Interleukin-6 Receptor: A new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum., 2005, 52, 687-93.</p><p>Yoshizaki K., Matsuda T., Nishimoto N., et al. Pathogenic significance of interleukin-6 (IL-6/BSF2) in Castleman`s disease. Blood, 1989, 74,1360-7. Lipsky P. Interleukin-6 and rheumatic diseases. Arthritis. Res. Ther., 2006. 8,S2.</p><p>Yokota Sh., Miyamae T., Imagawa T. et al Therapeutic efficacy of humanized anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthr Rheum., 2005, 52, 818-25.</p><p>Woo P., Wilkinson N., Prieure A.-M.. et al. Open label phase II trial of single doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvment. Arthritis Res. Ther., 2005. 7.1281-8.</p><p>Roony M., Varsani K., Martin P., et al. Tumor necrosis factor alpha and it soluble receptor in juvenile chronic arthritis. Rheumatol., 2000, 39, 432-8.</p><p>Madson KL, Moore TL, Lawrence JM 3rd, Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J.Rheumatol., 1994, 21,2359-63</p><p>Ou LS, See LC, Wu CJ et al. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin. Rheumatol., 2002, 1, 52-6.</p><p>Gattorno M, Picco P, Buoncompagni A et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann. Rheum. Dis., 1996, 55, 243-7.</p><p>De Benedetti F, Pignatti P, Massa M.. et al. Soluble tumor necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br. J. Rheumatol., 1997, 36, 581-8. Muzzaffer M.A., Dayer J.M., Feldman B.M. et al.</p><p>Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin-1 receptor antagonist reflect heterogeneity of the subgroup of juvenile rheumatiod arthritis. J.Rheumatol., 2002. 29, 1071-8.</p><p>De Benedetti F, Vivarelli M, Pignatti P. et al. Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis. J Rheumatol., 2000,27, 2246-50.</p><p>Lepore L, Pennesi M, Saletta S.. et al., Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin. Exp. Rheumatol., 1994,12,561-5</p><p>Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J. Rheumatol. 2001, 28, 2370.</p><p>De Benedetti F, Pignatti P,Bernassconi S. et al. Interleukin 8 and monocyte chemoattractant protein-1 in patient with juvenile rheumatoid arthritis: raletion to onset types, disease activity and synovial fluid leukocytes. J.Rheumatol., 1999, 26, 425-31.</p><p>De Benedetti F, Massa M, Pignatti P, Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J. Rheumatol., 1995, 22, 1581-5.</p><p>Mangge H, Gallistl S, Schauenstein K. Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J. Interferon Cytokine Res., 1999, 19,1005-</p><p>Silverman ED, Laxer RM, Nelson DL, Rubin LA. Soluble interleukin-2 receptor in juvenile rheumatoid arthritis. J.Rheumatol., 1991, 18, 1398-1402.</p><p>Huang JL, Kuo ML, Hung IJ.et al. Lowered IL-4- producing T cells and decreased IL-4 secretion in peripheral blood from subjects with juvenile rheumatoid arthritis. Chang Gung Med. J., 2001,24,:777-83.</p><p>Murray KJ, Grom AA, Thompson SD. et al. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J. Rheumatol., 1998, 25, 1388-98.</p><p>Raziuddin S., Bahabri S., Al-Dalaan. et al. A mixed Th1/Th2 cell cytokine response predominantes in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin. Immunol. Immunopathol. 1998, 86, 192-8.</p><p>Kawashima M., Yamamura M, Tanai M. et al. Levels of interleikin-18 and its binding inhibitors in the blood circulacion of patientsadult-onset Still`s disease. Arthritis Rheum., 2001, 44,550-60.</p><p>Maeno N.. Takei S., Nomura Y.. et al. Highly eleveted serum levels of interleikin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment to article by Kawashima et al. Arthritis Rheum., 2002, 46, 2539-41.</p><p>Cao L.F., Lu Y.M., Ma M.. et al. Levels of serum interleukin-15 and the expression of T-helper lymphocyte subsets in peripheral blood of children with juvenile rheumatoid arthritis. Zhongguo Dang Dai Er Ke Za Zhi., 2006, 8, 9-12.</p><p>Grom A.A., Murray K.J., Luyrnik L. et al. Pattern of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptor in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropaty. Arthritis Rheum., 1996, 39, 1703-10.</p><p>Kutukculer N, Caglayan S, Aydogdu F. Study of proinflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol., 1998, 17,288-92.</p><p>De Benedetti F, Robbioni P, Massa M. et al. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin. Exp. Rheumatol. 1992, 10,493-8.</p><p>Saxena N. Aggarwal N.. Misra R. Elevated concentrationis of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyaricular types of juvenile idiopathic arthritis. J.Rheumatol., 2005, 32, 1349-53.</p><p>Просвиров Е.Ю., Кельцев В.А., Рязанов В.В., и соавт. Морфофункциональные особенности иммунной системы при хронических артритах у детей. Научно-практическ. ревматол., 2003, 2 (прилож.), 86.</p><p>Pignatti P, Massa M, Travaglino P. et al. Activation- induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis. Clin. Exp. Rheumatol., 2001, 19,339-44.</p><p>Picco P. Gattorno M. Buonocompagni A. et al. Prolactin and interlukin-6 in prepubertal gerlls with juvenile chronic arthritis. J. Rheumatol., 1998, 25,247-351.</p><p>Gattorno M, Picco P, Vignola S. et al. Serum interleukin 12 concentration in juvenile chronic arthritis. Ann. Rheum. Dis., 1998,57, 25-8.</p><p>McCurdy D.K., Zaldivar F., Sandborg C. et al. Inteleukin-4 (IL-4) and IL-4 antagonist IL-4δ2 expression in synovial fluid from patients with juvenile rheumatoid arthritis (JRA). Arthritis Rheum., 1998, 41,SS49.</p><p>Jarvis J.N. Pathogenesis and mechanism of inflammation in the childhood rheumatic diseases. Curr. Opin. Rheumatol., 1998; 10,459-67.</p><p>Nikitina Zake L, Cimdina I, Rumba I, et al. Major histocompatibility complex class I chain related (MIC) A gene, TNFa microsatellite alleles and TNFB alleles in juvenile idiopathic arthritis patients from Latvia. Hum. Immunol.,2002, 63,418-23.</p><p>Ozen S, Alikasifoglu M, Bakkaloglu A, et al. Tumor necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatol., 2002, 41, 223-7.</p><p>McDowell T.L., Simons J.A., Ploski R., Duff G.W. A genetic assotiation between juvenile rheumatoid arthritis and a novel inteleukin-1α polymorphism. Arthritis Rheum., 1994, 38,221-8.</p><p>Heinzmann A., Jerkic S.P., Ganter K. et al. Association study of the IL13 variant Arg110Gln in atopic diseases and juvenile idiopathic arthritis. J. Allergy Clin. Immunol., 2003, 112,735-9.</p><p>Fishmann D.. Faulds G,, Jeffery R. et al. The effect of novel polymorfism in the interleukin-6 (IL-6) on IL-6 transcription and plasma IL-6 levels, and assotiation with systemic-onset juvenile chronic arthritis. J.Clin. 89 Invest., 1999, 102,1369-76.</p><p>Fife M.S., Guttierrez A., Ogilvie E.M. et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthr. Res. Ther., 2006. 8, R148.</p></div><br />
Рецензия
Для цитирования:
Федоров Е.С., Салугина С.О., Кузьмина Н.Н. Роль цитокиновой сети в регуляции воспаления при различных вариантах ювенильного артрита. Научно-практическая ревматология. 2009;47(3):74-89. https://doi.org/10.14412/1995-4484-2009-1316
For citation:
Fedorov E.S., Salugina S.O., Kuzmina N.N. Role of cytokine net in regulation of inflammation in different variants of juvenile arthritis. Rheumatology Science and Practice. 2009;47(3):74-89. (In Russ.) https://doi.org/10.14412/1995-4484-2009-1316
Просмотров:
1489
Послать статью по эл. почте 